Sulfanilamide


Sulfanilamide is a sulfonamide antibacterial drug. Chemically, it is an organic compound consisting of an aniline derivatized with a sulfonamide group. Powdered sulfanilamide was used by the Allies in World War II to reduce infection rates and contributed to a dramatic reduction in mortality rates compared to previous wars. Modern antibiotics have supplanted sulfanilamide on the battlefield; however, sulfanilamide remains in use today, primarily for treatment of vaginal yeast infections.
The term "sulfanilamides" is also used to describe a family of molecules containing these functional groups. Examples include:
As a sulfonamide antibiotic, sulfanilamide functions by competitively inhibiting enzymatic reactions involving para-aminobenzoic acid. PABA is needed in enzymatic reactions that produce folic acid, which acts as a coenzyme in the synthesis of purines and pyrimidines. Mammals do not synthesize their own folic acid so are unaffected by PABA inhibitors, which selectively kill bacteria.

History

Sulfanilamide was first prepared in 1908 by the Austrian chemist Paul Josef Jakob Gelmo as part of his dissertation for a doctoral degree from the Technische Hochschule of Vienna. It was patented in 1909.
Gerhard Domagk, who directed the testing of the prodrug Prontosil in 1935, and Jacques and Thérèse Tréfouël, who along with Federico Nitti and Daniel Bovet in the laboratory of Ernest Fourneau at the Pasteur Institute, determined sulfanilamide as the active form, are generally credited with the discovery of sulfanilamide as a chemotherapeutic agent. Domagk was awarded the Nobel Prize for his work.
In 1937 Elixir sulfanilamide, a medicine where the sulfanilamide was synthesized using diethylene glycol as a solvent, poisoned and killed more than 100 people as a result of acute kidney failure, prompting new US regulation for drug testing. In 1938, the Food, Drug and Cosmetic Act was passed.